Merck & Co Inc (MRK)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$121.17

Buy

$121.22

arrow-up$0.91 (+0.76%)

Prices updated at 01 Apr 2026, 18:57 EDT

Prices minimum 15 mins delay

Prices in USD

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

S&P 500

1.06%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Robert M. Davis

CEO

Mr. Robert M. Davis

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

75,000

Head office

126 East Lincoln Avenue

Rahway

United States

07065

+1 908 740-4000

investor_relations@merck.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Douglas M. Baker, Jr Independent Director	0.13m
Mr. Inge G. Thulin Independent Director	0.12m
Mr. Richard R. DeLuca, Jr Executive Vice President and President, Merck Animal Health	0.96m
Ms. Patricia F. Russo Independent Director	0.14m
Mr. Robert M. Davis Chairman of the Board, President and Chief Executive Officer	1.62m
Mr. Thomas Henry Glocer Lead Independent Director	0.19m
Ms. Pamela J. Craig Independent Director	0.15m
Dr. Risa J. Lavizzo-Mourey,M.D. Independent Director	0.12m
Ms. Kathy J. Warden Independent Director	0.13m
Dr. Paul B. Rothman, M.D. Independent Director	0.15m
Ms. Betty D. Larson Executive Vice President and Chief Human Resources Officer	0.60m
Mr. Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing	-
Ms. Mary Ellen Coe Independent Director	0.12m
Mr. Chirfi Guindo Senior Vice President, Human Health and Chief Marketing Officer	-
Ms. Jennifer Zachary Executive Vice President and General Counsel	-
Ms. Caroline A. Litchfield Executive Vice President and Chief Financial Officer	1.17m
Dr. Christine E. Seidman, M.D. Independent Director	0.13m
Mr. David Michael Williams Executive Vice President and Chief Information and Digital Officer	-
Dr. Stephen L. Mayo, PhD Independent Director	0.13m
Mr. Dean Y. Li, M.D.,PhD Executive Vice President and President, Merck Research Laboratories	1.45m
Mr. Jannie Oosthuizen Senior Vice President and President, Merck U.S. Human Health	-
Mr. Joseph Romanelli Senior Vice President and President, MSD, International Human Health	-
Mr. Dalton E. Smart, III Senior Vice President, Finance, Global Controller and Principal Accounting Officer	-
Mr. Brian Foard Executive Vice President and President Specialty, Pharma & Infectious Diseases	-
Mr. Surendralal L. Karsanbhai Independent Director	-
Mr. David R. Maraldo Senior Vice President, Human Health Operations	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	254,322,763
BlackRock Inc	214,876,600
State Street Corp	118,180,178
Vanguard	108,741,340
Wellington Management Company LLP	86,435,458

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2025	-
31 Dec 2025	-
31 Dec 2025	-
10 Nov 2025	-
03 Nov 2025	-
30 Sep 2025	-
30 Sep 2025	-
30 Sep 2025	-
04 Aug 2025	-
04 Aug 2025	-
04 Aug 2025	-
04 Aug 2025	-
04 Aug 2025	-
04 Aug 2025	-
30 Jun 2025	-
30 Jun 2025	-
30 Jun 2025	-
30 May 2025	-
30 May 2025	-
30 May 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.